Brief Summary
This study proposes a novel early intervention combining Intravenous (IV) amino acids plus in-bed cycle ergometry exercise to improve physical outcomes in critically ill patients. The investigators hypothesize that this innovative approach will improve short-term physical functioning outcomes (primary outcome), as well as amino acid metabolism, body composition, and patient-reported outcomes at 6-month follow-up.
Brief Title
Nutrition and Exercise in Critical Illness
Detailed Description
The evaluation of a combination of exercise and protein supplementation in intensive care unit (ICU) patients is novel and potentially very important. For instance, outside of the ICU, in other clinical conditions, the combination of protein supplementation and exercise improves protein synthesis, muscle mass, and muscle strength compared to protein or exercise alone.\[63-70\] Hence, an opportunity exists to improve ICU patients' physical outcomes via evaluating the combination of optimized protein intake and early exercise in the ICU setting.
The proposed intervention and hypothesis: The investigators propose a multi-centered Phase II RCT, with blinded outcomes assessment, of a combination of intravenous (IV) amino acid supplementation and early in-bed cycle ergometry exercise versus usual care in ICU patients requiring mechanical ventilation. The investigators hypothesize that this novel combined intervention will: (1) improve physical functioning at hospital discharge; (2) reduce muscle wasting with improved amino acid metabolism and protein synthesis in-hospital; and (3) improve health-related quality of life, physical functioning, and healthcare resource utilization at 6 months after enrollment. Preliminary data show feasibility and safety of IV amino acids and the proposed exercise intervention. The investigators have chosen a primary outcome that correlates well with long-term outcomes including mortality, hospitalization, and quality of life. \[54\] If this Phase II trial is positive, investigators will seek funding for a Phase III RCT to demonstrate sustained improvements with a longer-term patient-centered primary outcome and to examine the feasibility, and facilitators/barriers of delivery of this intervention by ICU nurses, physical therapists, and others. If proven effective, this combined intervention has potential to revolutionize care of ICU patients and have a major public health impact on the growing number of ICU survivors.
Objectives: To demonstrate that the innovative combination of amino acid supplementation plus early in-bed cycle ergometry exercise improves physical outcomes of ICU patients.
Specific Aims of Full Phase II RCT:
1. Short-term performance-based physical function outcomes. To determine if a combined IV amino acid supplementation and in-bed cycle ergometry exercise intervention, compared to usual care, improves in hospital muscle strength and performance-based physical functioning outcomes in critically ill patients, using a primary endpoint of six-minute walk distance (6MWD) at hospital discharge.
2. Body composition. To determine if the combined intervention, compared to usual care, improves amino acid utilization and decreases muscle wasting in ICU patients (secondary endpoints).
3. Patient-reported outcomes and health care utilization at 6 months. To determine if the combined intervention, compared to usual care, improves physical functioning, health-related quality of life, and healthcare utilization at 6 months after study enrollment (secondary endpoints).
NEXIS Flame mechanisitic Ancillary sub study:
In the proposed sub-study, the addition of bronchoaveloar lavages, blood sampling and muscle sampling measures during the participant's ICU stay will provide the ability to examine the effects of the NEXIS intervention on inflammation as a possible mechanism for improved muscle weakness.
Specific Aims of the NEXIS FLAME mechanistic ancillary study:
1. To determine if the NEXIS intervention attenuates the release of IL-17 and related cytokines to reduce systemic inflammation in humans.
2. To determine if the NEXIS intervention reduces lung injury and neutrophilic lung inflammation in humans.
3. To determine if the NEXIS intervention attenuates skeletal muscle fiber atrophy via down regulation of muscle proteolytic pathways.
4. To determine if the NEXIS intervention, and exercise specifically, reduces the content of inflammatory cells in skeletal muscle.
The proposed intervention and hypothesis: The investigators propose a multi-centered Phase II RCT, with blinded outcomes assessment, of a combination of intravenous (IV) amino acid supplementation and early in-bed cycle ergometry exercise versus usual care in ICU patients requiring mechanical ventilation. The investigators hypothesize that this novel combined intervention will: (1) improve physical functioning at hospital discharge; (2) reduce muscle wasting with improved amino acid metabolism and protein synthesis in-hospital; and (3) improve health-related quality of life, physical functioning, and healthcare resource utilization at 6 months after enrollment. Preliminary data show feasibility and safety of IV amino acids and the proposed exercise intervention. The investigators have chosen a primary outcome that correlates well with long-term outcomes including mortality, hospitalization, and quality of life. \[54\] If this Phase II trial is positive, investigators will seek funding for a Phase III RCT to demonstrate sustained improvements with a longer-term patient-centered primary outcome and to examine the feasibility, and facilitators/barriers of delivery of this intervention by ICU nurses, physical therapists, and others. If proven effective, this combined intervention has potential to revolutionize care of ICU patients and have a major public health impact on the growing number of ICU survivors.
Objectives: To demonstrate that the innovative combination of amino acid supplementation plus early in-bed cycle ergometry exercise improves physical outcomes of ICU patients.
Specific Aims of Full Phase II RCT:
1. Short-term performance-based physical function outcomes. To determine if a combined IV amino acid supplementation and in-bed cycle ergometry exercise intervention, compared to usual care, improves in hospital muscle strength and performance-based physical functioning outcomes in critically ill patients, using a primary endpoint of six-minute walk distance (6MWD) at hospital discharge.
2. Body composition. To determine if the combined intervention, compared to usual care, improves amino acid utilization and decreases muscle wasting in ICU patients (secondary endpoints).
3. Patient-reported outcomes and health care utilization at 6 months. To determine if the combined intervention, compared to usual care, improves physical functioning, health-related quality of life, and healthcare utilization at 6 months after study enrollment (secondary endpoints).
NEXIS Flame mechanisitic Ancillary sub study:
In the proposed sub-study, the addition of bronchoaveloar lavages, blood sampling and muscle sampling measures during the participant's ICU stay will provide the ability to examine the effects of the NEXIS intervention on inflammation as a possible mechanism for improved muscle weakness.
Specific Aims of the NEXIS FLAME mechanistic ancillary study:
1. To determine if the NEXIS intervention attenuates the release of IL-17 and related cytokines to reduce systemic inflammation in humans.
2. To determine if the NEXIS intervention reduces lung injury and neutrophilic lung inflammation in humans.
3. To determine if the NEXIS intervention attenuates skeletal muscle fiber atrophy via down regulation of muscle proteolytic pathways.
4. To determine if the NEXIS intervention, and exercise specifically, reduces the content of inflammatory cells in skeletal muscle.
Central Contacts
Central Contact Role
Contact
Central Contact Phone
403-915-5573
Central Contact Email
dkh2@queensu.ca
Central Contact Role
Contact
Central Contact Email
Shawna.Froese@queensu.ca
Completion Date
Completion Date Type
Estimated
Conditions
Acute Respiratory Failure
Eligibility Criteria
Inclusion Criteria:
1. ≥18 years old.
2. Requiring mechanical ventilation with actual or expected total duration of mechanical ventilation ≥ 48 hours.
3. Expected ICU stay ≥ 4 days after enrollment (to permit adequate exposure to the proposed intervention).
Exclusion Criteria:
1. \>96 continuous hours of mechanical ventilation before enrollment.
2. Expected death or withdrawal of life-sustaining treatments within this hospitalization.
3. No expectation for any nutritional intake within the subsequent 72 hours.
4. Severe chronic liver disease (MELD score ≥20) or acute fulminant hepatitis.
5. Documented allergy to the amino acid intervention.
6. Metabolic disorders involving impaired nitrogen utilization
7. Not ambulating independently prior to illness that lead to ICU admission (use of gait aid permitted).
8. Pre-existing primary systemic neuromuscular disease (e.g. Guillain Barre).
9. Neuromuscular blocker infusion (eligible once infusion discontinued if other inclusion criteria met).
10. Intracranial or spinal process affecting motor function
11. Pre-existing cognitive impairment or language barrier that prohibits outcomes assessment.
12. Patients in hospital \>5 days prior to ICU admission
13. Lower extremity impairments that prevent cycling (e.g. amputation, knee/hip injury).
14. Remaining intubated for airway protection only
15. Weight ≥150kg
16. Physician declines patient enrollment
17. Insufficient IV access
18. Pregnant
19. Incarcerated
1. ≥18 years old.
2. Requiring mechanical ventilation with actual or expected total duration of mechanical ventilation ≥ 48 hours.
3. Expected ICU stay ≥ 4 days after enrollment (to permit adequate exposure to the proposed intervention).
Exclusion Criteria:
1. \>96 continuous hours of mechanical ventilation before enrollment.
2. Expected death or withdrawal of life-sustaining treatments within this hospitalization.
3. No expectation for any nutritional intake within the subsequent 72 hours.
4. Severe chronic liver disease (MELD score ≥20) or acute fulminant hepatitis.
5. Documented allergy to the amino acid intervention.
6. Metabolic disorders involving impaired nitrogen utilization
7. Not ambulating independently prior to illness that lead to ICU admission (use of gait aid permitted).
8. Pre-existing primary systemic neuromuscular disease (e.g. Guillain Barre).
9. Neuromuscular blocker infusion (eligible once infusion discontinued if other inclusion criteria met).
10. Intracranial or spinal process affecting motor function
11. Pre-existing cognitive impairment or language barrier that prohibits outcomes assessment.
12. Patients in hospital \>5 days prior to ICU admission
13. Lower extremity impairments that prevent cycling (e.g. amputation, knee/hip injury).
14. Remaining intubated for airway protection only
15. Weight ≥150kg
16. Physician declines patient enrollment
17. Insufficient IV access
18. Pregnant
19. Incarcerated
Inclusion Criteria
Inclusion Criteria:
1. ≥18 years old.
2. Requiring mechanical ventilation with actual or expected total duration of mechanical ventilation ≥ 48 hours.
3. Expected ICU stay ≥ 4 days after enrollment (to permit adequate exposure to the proposed intervention).
1. ≥18 years old.
2. Requiring mechanical ventilation with actual or expected total duration of mechanical ventilation ≥ 48 hours.
3. Expected ICU stay ≥ 4 days after enrollment (to permit adequate exposure to the proposed intervention).
Gender
All
Gender Based
false
Healthy Volunteers
No
Last Update Post Date
Last Update Post Date Type
Actual
Last Update Submit Date
Minimum Age
18 Years
NCT Id
NCT03021902
Org Class
Other
Org Full Name
Clinical Evaluation Research Unit at Kingston General Hospital
Org Study Id
The NEXIS Trial
Overall Status
Unknown status
Phases
Phase 2
Primary Completion Date
Primary Completion Date Type
Estimated
Official Title
Nutrition and Exercise in Critical Illness (The NEXIS Trial): A Randomized Trial of Combined Cycle Ergometry and Amino Acids in the ICU
Primary Outcomes
Outcome Description
6-minute walk distance
Outcome Measure
Physical functioning
Outcome Time Frame
Hospital discharge (up to 26 weeks after randomization)
Secondary Outcomes
Outcome Description
MRC Sum-score (Medical Research Council (MRC) Scale for Muscle Strength). Subscales scored 0-5, where 5 is normal. Total score is the sum of the 6 upper extremity subscales.
Outcome Time Frame
Hospital discharge (up to 26 weeks after randomization)
Outcome Measure
Overall strength-upper extremity
Outcome Description
MRC Sum-score (Medical Research Council (MRC) Scale for Muscle Strength). Subscales scored 0-5, where 5 is normal. Total score is the sum of the 6 lower extremity subscales.
Outcome Time Frame
Hospital discharge (up to 26 weeks after randomization)
Outcome Measure
Overall strength-lower extremity
Outcome Description
Hand held dynamometry
Outcome Time Frame
Hospital discharge (up to 26 weeks after randomization)
Outcome Measure
Quadriceps force-lower extremity strength
Outcome Description
Hand held dynamometry
Outcome Time Frame
ICU and hospital discharge (up to 26 weeks after randomization)
Outcome Measure
Distal strength-hand grip strength
Outcome Description
Short Physical Performance Battery
Outcome Time Frame
ICU and hospital discharge (up to 26 weeks after randomization)
Outcome Measure
Overall Physical Functional status - Short Physical Performance Battery
Outcome Description
Functional Status Score - ICU 5 items are performed: rolling, transfer from supine to sit, sitting at the edge of bed, transfer from sit to stand, and walking Each task is evaluated using an eight-point ordinal scale ranging from 0 (unable to perform) to 7 (complete independence) Item scores are summed The total score ranges from 0-35, with higher scores indicating better physical functioning.
Outcome Time Frame
ICU and hospital discharge (up to 26 weeks after randomization)
Outcome Measure
Overall Physical Functional status - Functional Status Score - ICU
Outcome Description
Chart review
Outcome Time Frame
ICU and hospital discharge (up to 26 weeks after randomization)
Outcome Measure
Mortality
Outcome Description
Chart review
Outcome Time Frame
ICU and hospital discharge (up to 26 weeks after randomization)
Outcome Measure
Length of ventilation
Outcome Description
Chart review
Outcome Time Frame
ICU and hospital discharge (up to 26 weeks after randomization)
Outcome Measure
ICU stay
Outcome Description
Chart review
Outcome Time Frame
ICU and hospital discharge (up to 26 weeks after randomization)
Outcome Measure
Hospital stay
Outcome Description
Chart review
Outcome Time Frame
Hospital discharge (up to 26 weeks after randomization)
Outcome Measure
ICU readmission
Outcome Description
Chart review
Outcome Time Frame
Hospital discharge (up to 26 weeks after randomization)
Outcome Measure
Re-intubation
Outcome Description
Chart review
Outcome Time Frame
Hospital discharge (up to 26 weeks after randomization)
Outcome Measure
Hospital-acquired infections
Outcome Description
Chart review
Outcome Time Frame
Hospital discharge (up to 26 weeks after randomization)
Outcome Measure
Discharge location (e.g. home vs. rehab)
Outcome Description
Ultrasound of quadriceps
Outcome Time Frame
Enrollment, hospital discharge, & ICU discharge (up to 26 weeks after randomization)
Outcome Measure
Body composition - Ultrasound
Outcome Description
Chest CT
Outcome Time Frame
Enrollment, hospital discharge, & ICU discharge (up to 26 weeks after randomization)
Outcome Measure
Body composition - CT - Chest when clinically available
Outcome Description
Abdominal CT scan at 3rd lumbar vertebra
Outcome Time Frame
Enrollment, hospital discharge, & ICU discharge (up to 26 weeks after randomization)
Outcome Measure
Body composition - CT - Abdominal Scan when clinically available
Outcome Description
36-Item Short Form Health Survey (SF-36) All items are scored so that a high score defines a more favorable health state.
Each item is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100 Items in the same scale are averaged together to create the 8 scale scores. Items that are left blank (missing data) are not taken into account when calculating the scale scores.
Scale scores represent the average for all items in the scale that the respondent answered.
Each item is scored on a 0 to 100 range so that the lowest and highest possible scores are 0 and 100 Items in the same scale are averaged together to create the 8 scale scores. Items that are left blank (missing data) are not taken into account when calculating the scale scores.
Scale scores represent the average for all items in the scale that the respondent answered.
Outcome Time Frame
Telephone survey at 6 months
Outcome Measure
Health-related quality of life - SF-36
Outcome Description
EuroQol Group standardized measure of health status (EQ-5D-5L)
Outcome Time Frame
Telephone survey at 6 months
Outcome Measure
Health-related quality of life - EQ-5D-5L
Outcome Description
Katz Index of Independence in Activities of Daily Living (Katz ADL) Total score where 6 = High (patient independent) 0 = Low (patient very dependent)
Outcome Time Frame
Hospital discharge (proxy) and telephone survey at 6 months
Outcome Measure
Physical functioning - Katz ADL
Outcome Description
Lawton Instrument Activities of Daily Living Scale (Lawton IADL) A summary score ranges from 0 (low function, dependent) to 8 (high function, independent) for women and 0 through 5 for men to avoid potential gender bias.
Outcome Time Frame
Telephone survey at 6 months
Outcome Measure
Physical functioning - Lawton IADL
Outcome Description
Return to baseline work/activity
Outcome Time Frame
Telephone survey at 6 months
Outcome Measure
Physical functioning/participation - return to work
Outcome Description
Living location
Outcome Time Frame
Telephone survey at 6 months
Outcome Measure
Physical functioning/participation - living location
Outcome Description
MoCA-BLIND The total possible score is 22 points; a score of 18 or above is considered normal
Outcome Time Frame
Telephone survey at 6 months
Outcome Measure
Mental and Cognitive Functioning - MoCA-BLIND
Outcome Description
Hospital Anxiety and Depression Scale The HADS questionnaire has seven items each for depression and anxiety subscales. Scoring for each item ranges from zero to three, with three denoting highest anxiety or depression level. A total subscale score of \>8 points out of a possible 21 denotes considerable symptoms of anxiety or depression.
Outcome Time Frame
Telephone survey at 6 months
Outcome Measure
Mental and Cognitive Functioning - HADS
Outcome Description
Impact of Events Scale Scoring for each item ranges from 0-4 Total score ranges from 0-88, where a total score of 33 or over signifies the likely presence of PTSD
Outcome Time Frame
Telephone survey at 6 months
Outcome Measure
Mental and Cognitive Functioning - IES-R
Outcome Description
Admission to ICU, hospital, rehabilitation \& nursing facility
Outcome Time Frame
Telephone survey at 6 months
Outcome Measure
Health Care Resource Utilization
Outcome Description
Whole Body DEXA Scan
Outcome Time Frame
At Hospital Discharge
Outcome Measure
Body composition - DEXA Scan
Outcome Description
Fat-free and fat mass can be measured with D2O in body fluids using gas chromatography-tandem mass spectrometry.
Outcome Time Frame
Enrollment, Days 1-7
Outcome Measure
Body Composition - Heavy water
Outcome Description
Muscle protein synthesis will be analyzed with chromatography and mass spectrometry techniques.
Outcome Time Frame
Enrollment, Days 1-7
Outcome Measure
Plasma and muscle protein synthesis - Heavy water
Outcome Description
Blood IL-17, IL-23, IL-6, TNFα, CXCK1, CXCL5, CXCL8, CCL2, SP-D, KL-6, vWF, and leukocyte counts with differential
Outcome Time Frame
Enrollment, Days 3, 5, and 8
Outcome Measure
NEXIS FLAME - Circulating inflammatory mediators
Outcome Description
Bronchoalveolar lavage neutrophil counts, IL-17A, CXCL5, and protein
Outcome Time Frame
Enrollment, Day 5
Outcome Measure
NEXIS FLAME - Lung Inflammation
Outcome Description
Single muscle fiber cross-sectional area (CSA), UPS expression, MuRF1 expression, myosin protein content (all from vastus lateralis sampling)
Outcome Time Frame
Enrollment, Day 5
Outcome Measure
NEXIS FLAME - Muscle area
Outcome Description
Muscle macrophages (CD45+, CD206+)
Outcome Time Frame
Enrollment, Day 5
Outcome Measure
NEXIS FLAME - Muscle inflammation
Start Date
Start Date Type
Actual
Status Verified Date
First Post Date
First Post Date Type
Estimated
First Submit Date
First Submit QC Date
Std Ages
Adult
Older Adult
Locked Fields
Render the field
Maximum Age Number (converted to Years and rounded down)
999
Minimum Age Number (converted to Years and rounded down)
18
Investigators
Investigator Type
Principal Investigator
Investigator Name
Matthias Eikermann
Investigator Email
meikermann@montefiore.org